Company Business and Management Condition

HUMAN LIFE SCIENCE Holding Corp. (hereafter the " HUMAN LIFE ") is an organization that has been registered in the Cayman Islands of UK in July 5, 2001. HUMAN LIFE holds the patent of biological cancer-cure drug with wide market (During 20 years from 2005 to 2024 in Greater (China). The common name of the drug is called UKRAIN (the Registration Number in America National Cancer Institution: NSC-631570) (source: http://dtp.nci.nih.gov/, Publish number of the patent authorized by State Intellectual Property Office of P.R.C.: CN1706845A).

HUMAN LIFE SCIENCE Holding Corp. is actively merging the pharmaceutical companies with GSP certificates, which are located respectively in China Beijing, Baoding, Shijiazhuang, Tangshan, Taiyuan, Langfang, Dezhou City. HUMAN LIFE's market share and profit are expected to grow steadily upon completion of these mergers at the end of the third quarter, 2008.

HUMAN LIFE's patented biological cancer-cure drug - UKRAIN has been approved for clinical use in Germany, Austria, Switzerland, Ukraine, Georgia, Turkmenistan and Azerbaijan. Based on clinical statistics in the seven countries, UKRAIN is proved to be the most effective cancer-cure drug with the following treatment results in comparison with other cancer-treatment drugs in market:
1. UKRAIN is the most powerful cancer-treatment drug for its ability of killing cancer cell.
2. UKRAIN is accounted as the least negligible to the extent of accidentally injuring normal cell.
3. UKRAIN delivers the maximal survival rate that extends cancer patients' survival time to the longest.
(Source: Center for Ontological, Endocrinological and Minimal-access Surgery, University of Ulm, Slicherstr 36, 89231 Neu-Ulm, Germany Frank gansauge@eurosurgery be)

Before UKRAIN was used in Chinese hospitals,"Import Drug License", the documents about applying "Import License" that is required in DRUG REGISTRATION REGULATION OF P.R.C. issued by SFDA in P.R.C have to be completed.

Timely Chinese government issued Drug Registration Special Approval process Implementing Method in the end of 2007. (Source: http://www.sda.gov.cn/ ). HUMAN LIFE will fully use this policy to apply special approval process for UKRAIN in SFDA and get the Import Drug License as soon as possible.

In order to apply UKRAIN in Chinese hospitals, an "Import Drug License" needs to be obtained per China SFDA's regulations. Accordingly, HUMAN LIFE conducted application documents in late 2007.

Right before HUMAN LIFE submitting the application, SFDA released Drug Registration Special Approval Process Implementing Method at the end of 2007 (Source: http://www.sda.gov.cn/ ), which enabled HUMAN LIFE to follow special approval process and expedite its obtaining Import Drug License for UKRAIN.

Phase I, II and III clinical trials of UKRAIN as a biological cancer-cure drug have been completed in Western countries. HUMAN LIFE has submitted to SFDA the pre-clinical research files and clinical trial summary reports as a part of the application documents for review. HUMAN LIFE is looking forward to SFDA issuing UKRAIN the Import Drug License, which will benefit Chinese cancer patients to get their therapy from UKRAIN in a timely manner.

With successful registration of UKRAIN in seven countries, i.e., Germany, Austria, Switzerland, Ukraine, Georgia, Turkmenistan and Azerbaijan, HUMAN LIFE has become a skilled registrant and is ready to enter its eighth market, China.

Profitability potential of UKRAIN is extremely strong, given the fact that HUMAN LIFE's business strategy is directed with two key objectives:
a. Providing the patients in hospitals the best therapy efficiency.
b. Firm and steady profit mode.

Most cancer-treatment drugs need Doctors' prescription. OTC (drug over-the-counter) is only auxiliary source for cancer patients, not the mainstream. There are nearly 100 cancer-treatment drugs in Chinese market for Doctors to prescribe, but all those drugs experience high mortality rate. According to a wide-range survey conducted by HUMAN LIFE with different hospitals, from different provinces and cities in China what Doctors/patients concern the most is how to lower the mortality rate without reducing treatment efficiency.

With better understanding of the market after the survey, HUMAN LIFE confidently adopted a brand new approach to introduce its proprietary cancer-cure drug - UKRAIN, which is the answer and remedy to Doctors/patients' concern. Instead of the traditional marketing strategy, HUMAN LIFE launched lectures/seminars of UKRAIN directly and continuously to hospitals and medical institutes. As of today, Doctors from the following 73 hospitals have attended the lectures/seminars, and the feedback was positive: Doctors are eager to use UKRAIN for their patients.

The list of hospitals:
1. Cancer Institute & Hospital Chinese Academy of Medical SCIENCE
2. Peking Union Hospital
3. The First Affiliated Hospital of Peking University
4. Beijing Ditan Hospital
5. The Fourth People's Hospital of Shenyang
6. Tianjin Cancer Hospital
7. Wuwei Cancer Hospital
8. The Third People's Hospital of Fuxin
9. Beijing Cancer Hospital
10. Shanghai Changzheng Hospital
11. Shanghai Jingan District Central Hospital
12. The First People's Hospital of Shanghai
13. The seventh people's hospital of Shanghai
14. Shanghai Humanity hospital
15. Shanghai Chest Hospital
16. The eighth people's hospital of Shanghai
17. The First Affiliated Hospital of Jinlin University
18. Shanxi Provincial Cancer Hospital
19. The Second Hospital of Heilongjiang Province
20. The Second Hospital of Ha er'bin
21. Jinlin Provincial Cancer Hospital
22. North China Electronic Power General Hospital (Beijing)
23. Heilongjiang Provincial Cancer Hospital
24. Huashan Hospital Affiliated to Shanghai Fudan University
25. The First Affiliated Hospital of West China Medical University
26. Zhejiang University Medical College Affiliated Sir Run Run Shaw Hospital
27. Union Hospital Affiliated to Huazhong University of Science and Technology
28. Shanghai Changhai Hospital Affiliated to the Second Military Medical University
29. The Second Affiliated Hospital of Zhejiang University Medical College
30. Zhongshan Hospital Affiliated to Shanghai Fudan University
31. Shanghai Eastern Hepatobiliary Hospital
32. Renji Hospital Affiliated to Shanghai No.2 Medical University
33. The Fifth People's Hospital Affiliated to Shanghai Fudan University
34. Shanghai Huadong Hospital
35. The Eighty-fifth PLA Hospital of Shanghai
36. Beijing General PLA Hospital
37. Xuan Wu Hospital Affiliated to Capital Medical University
38. Nanfang Hospital Affiliated to the First Military Medical University of Guangzhou
39. The First Affiliate Hospital of Nanjing Medical University
40. Zhong Da Hospital Affiliated to Nanjing Southeast University
41. Zhejiang Provincial Cancer Hospital
42. The Sixth People's Hospital of Xiaoshan District of Hangzhou
43. The First People's Hospital of Qiqihaer' City Heilongjiang Province.
44. Guangzhou Zhujiang Hospital Affiliated to the First Military Medical University
45. Qilu Hospital of Shandong University
46. Zunyi Medical College Affiliated Hospital
47. General Hospital of Chengdu Military Area.
48. The Second Affiliated Hospital of Kunmin Medical College
49. The First Hospital of Xi'an Jiao Tong University
50. Xiangya Hospital of Centre-South University
51. The Fifth Hospital of Guangxi Medical University
52. Baogang Hospital Affiliated to Shanghai No.2 Medical University
53. The First Hospital Affiliated to Jiamusi College of Heilongjiang
54. The Second People's Hospital of Kashi District of Xinjiang
55. Ruijin Hospital Affiliated to Shanghai No.2 Medical University
56. Zhejiang Taizhou City Hospital
57. Nanfang Hospital of Guangzhou No.1 Medical University
58. Jiangbei People's Hospital Affiliated to Medical College of Nanjing Southeast University
59. The First Affiliated Hospital of Wenzhou Medical College
60. People's Liberation Army one-five-two Hospital
61. Taihe Hospital of Shiyan City Hubei Province
62. Yunyang Medical College Affiliated Hospital of Hubei Province
63. The Third Affiliated Hospital of Shihezi University Xinjiang Province
64. The Second Hospital Affiliated to Suzhou University
65. The Fourth People's Hospital of Chongqing
66. General Hospital of Panjiang Coal and Electricity Group Guizhou Province
67. Shekou District People's Hospital Of Shenzhen
68. Molecular Biology Laboratory of Fudan University Affiliated Cancer Hospital
69. Jiading Hospital Affiliated to Shanghai No.2 Medical University
70. The People's Hospital of Dongyang City Guangdong Province
71. The Central People's Hospital of Zumadian City Henan Province
72. The First Affiliated Hospital of Nanjin Medical University
73. The Second People's Hospital of Huaihua City Hunan Province.

In response to the positive feedback, HUMAN LIFE constructed its market strategy explicitly: "Select top 47 hospitals that are licensed to league from the hundreds to establish a special hospital chain system for cancer therapy."

HUMAN LIFE International Cancer-Cure Center